MA33602B1 - Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide - Google Patents

Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide

Info

Publication number
MA33602B1
MA33602B1 MA34713A MA34713A MA33602B1 MA 33602 B1 MA33602 B1 MA 33602B1 MA 34713 A MA34713 A MA 34713A MA 34713 A MA34713 A MA 34713A MA 33602 B1 MA33602 B1 MA 33602B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
rheumatoid arthritis
ribamipid
treatment
arthritis containing
Prior art date
Application number
MA34713A
Other languages
Arabic (ar)
English (en)
Inventor
Jun-Ki Min
Mi-La Cho
Yun-Ju Woo
Hye-Jwa Oh
Joo-Yeon Jhun
Geun-Hyeog Lee
Se-Wan Park
Jin-Ha Park
Eun-Young Kwak
Original Assignee
Catholic Univ Ind Acad Coop
Hanlim Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catholic Univ Ind Acad Coop, Hanlim Pharmaceutical Co Ltd filed Critical Catholic Univ Ind Acad Coop
Publication of MA33602B1 publication Critical patent/MA33602B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

La présente invention a pour objet une composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide et un support pharmaceutiquement acceptable. La composition pharmaceutique peut se présenter sous la forme d'une administration orale, et de préférence encore, la composition pharmaceutique peut avoir une forme posologique orale solide d'un comprimé ou d'une capsule. En outre, la composition pharmaceutique peut être formulée dans une forme posologique unitaire appropriée à une administration orale avec une posologie du rébamipide de 0,5 à 50 mg/kg, et de préférence encore de 0,6 à 6 mg/kg.
MA34713A 2009-08-25 2012-03-22 Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide MA33602B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090078547A KR101104634B1 (ko) 2009-08-25 2009-08-25 레바미피드를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
PCT/KR2009/005753 WO2011025086A1 (fr) 2009-08-25 2009-10-08 Composition pharmaceutique permettant de prévenir ou de traiter l’arthrite rhumatoïde, contenant du rébamipide

Publications (1)

Publication Number Publication Date
MA33602B1 true MA33602B1 (fr) 2012-09-01

Family

ID=43628165

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34713A MA33602B1 (fr) 2009-08-25 2012-03-22 Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide

Country Status (10)

Country Link
US (1) US8691842B2 (fr)
EP (1) EP2471535B1 (fr)
JP (1) JP2013503153A (fr)
KR (1) KR101104634B1 (fr)
CN (1) CN102481298A (fr)
BR (1) BR112012003617A2 (fr)
CA (1) CA2770778C (fr)
MA (1) MA33602B1 (fr)
RU (1) RU2496497C1 (fr)
WO (1) WO2011025086A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101182114B1 (ko) * 2010-03-05 2012-09-12 한림제약(주) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
KR101317507B1 (ko) * 2010-08-30 2013-10-15 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물
JP5707137B2 (ja) * 2011-01-06 2015-04-22 学校法人東京女子医科大学 レバミピドの骨粗鬆症治療用途
KR101395984B1 (ko) * 2011-10-21 2014-05-16 가톨릭대학교 산학협력단 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
KR101436728B1 (ko) 2012-03-20 2014-09-02 가톨릭대학교 산학협력단 골수유래억제세포 및 레바미피드를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
CN109381466A (zh) * 2017-08-02 2019-02-26 中国药科大学 促进糖尿病病人伤口愈合的治疗剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1740003A1 (ru) * 1989-05-24 1992-06-15 Киевский Медицинский Институт Им.Акад.А.А.Богомольца Способ лечени ревматоидного артрита
RU1816457C (ru) * 1990-12-13 1993-05-23 Московский медицинский стоматологический институт им.Н.А.Семашко Способ лечени ревматоидного артрита
US5637597A (en) * 1993-10-21 1997-06-10 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives for inhibiting production of interleukin-8
EP1336602A1 (fr) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Prodrogues nitrées capable de libérer du monoxyde d'azote de manière controlée et sélective ainsi que leur utilisation pour la prévention et le traitement de maladies inflammatoires, ischémiques et proliferatives
JP2004155781A (ja) * 2002-10-17 2004-06-03 Tokuyuki Namiki 口腔内速崩錠

Also Published As

Publication number Publication date
WO2011025086A1 (fr) 2011-03-03
EP2471535A1 (fr) 2012-07-04
JP2013503153A (ja) 2013-01-31
KR101104634B1 (ko) 2012-01-12
US8691842B2 (en) 2014-04-08
KR20110021016A (ko) 2011-03-04
CN102481298A (zh) 2012-05-30
EP2471535A4 (fr) 2013-03-06
BR112012003617A2 (pt) 2016-02-23
CA2770778A1 (fr) 2011-03-03
CA2770778C (fr) 2016-06-14
RU2496497C1 (ru) 2013-10-27
US20120172394A1 (en) 2012-07-05
EP2471535B1 (fr) 2018-05-23

Similar Documents

Publication Publication Date Title
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
MA30807B1 (fr) Compositions pharmaceutiques.
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
MA34296B1 (fr) Composition retard injectable antipsychotique
MA32027B1 (fr) Preparation de capsules
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
NZ599847A (en) Pharmaceutical composition comprising a glp-1 agonist and methionine
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
NZ596879A (en) Tamper resistant dosage form comprising a matrix and melt - extruded particulates comprising a drug
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA45972B1 (fr) Unité posologique orodispersible contenant un composant d'estétrol
MX346335B (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
MA30466B1 (fr) Nouvelle forme d'administration du racecadotril
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
MX2010007083A (es) Combinacion anti-retroviral.
EA200870449A1 (ru) Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
MA29722B1 (fr) Schema posologique pour le prasugrel
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
NZ595127A (en) Stable pharmaceutical composition for atherosclerosis
MA34313B1 (fr) Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan
WO2008030830A3 (fr) Composition à libération prolongée et son procédé d'utilisation
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
MX2010003441A (es) Formulaciones galenicas de alisquireno y valsartan.
TR200101719T2 (tr) Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı